• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

AJNR Am J Neuroradiol . Post-COVID-19 Brain [18F] FDG-PET Findings: A Retrospective Single-Center Study in the United States

tetano

Editor, Senior Moderator
AJNR Am J Neuroradiol


. 2023 Apr 27.
doi: 10.3174/ajnr.A7863. Online ahead of print. Post-COVID-19 Brain [[SUP]18[/SUP]F] FDG-PET Findings: A Retrospective Single-Center Study in the United States

P Debs[SUP] 1 [/SUP], N Khalili[SUP] 1 [/SUP], L Solnes[SUP] 1 [/SUP], A Al-Zaghal[SUP] 1 [/SUP], H I Sair[SUP] 1 [/SUP], V Yedavalli[SUP] 1 [/SUP], L P Luna[SUP] 2 [/SUP]



Affiliations
Abstract

Background and purpose: The pathophysiology of neurologic manifestations of postacute sequelae of Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infection is not clearly understood. Our aim was to investigate brain metabolic activity on [[SUP]18[/SUP]F] FDG-PET/CT scans in patients with a history of coronavirus disease 2019 (COVID-19) infection before imaging.
Materials and methods: This retrospective study included 45 patients who underwent [[SUP]18[/SUP]F] FDG-PET/CT imaging for any reason and had, at least once, tested positive for COVID-19 at any time before imaging. Fifteen patients had available [[SUP]18[/SUP]F] FDG-PET scans obtained under identical conditions before the infection. A group of 52 patients with melanoma or multiple myeloma who underwent [[SUP]18[/SUP]F] FDG-PET/CT were used as controls. Whole-brain 2-sample t test analysis was performed using SPM software to identify clusters of hypo- and hypermetabolism and compare brain metabolic activity between patients with COVID-19 and controls. Paired sample t test comparison was also performed for 15 patients, and correlations between metabolic values of clusters and clinical data were measured.
Results: Compared with the control group, patients with a history of COVID-19 infection exhibited focal areas of hypometabolism in the bilateral frontal, parietal, occipital, and posterior temporal lobes and cerebellum (P = .05 uncorrected at the voxel level, family-wise error-corrected at the cluster level) that peaked during the first 2 months, improved to near-complete recovery around 6 months, and disappeared at 12 months. Hypermetabolism involving the brainstem, cerebellum, limbic structures, frontal cortex, and periventricular white matter was observed only at 2-6 months after infection. Older age, neurologic symptoms, and worse disease severity scores positively correlated with the metabolic changes.
Conclusions: This study demonstrates a profile of time-dependent brain PET hypo- and hypermetabolism in patients with confirmed SARS-CoV-2 infection.


 
Back
Top Bottom